Trial Profile
Phase 1 Study of the Safety and Immunogenicity of RiVax With Alum in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Sep 2016
Price :
$35
*
At a glance
- Drugs Ricin vaccine (Primary) ; Alum
- Indications Ricin poisoning
- Focus Adverse reactions
- 19 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Aug 2012 According to a Soligenix media release, this trial was supported by a combination of grants including a $940,000 grant from the Office of Orphan Products Development (OOPD) of the Food and Drug Administration (FDA).
- 28 Aug 2012 Planned End Date changed from 1 Jan 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.